Cadrenal Therapeutics, Inc. (NASDAQ:CVKD – Get Free Report) was the target of a large increase in short interest in the month of December. As of December 15th, there was short interest totalling 85,300 shares, an increase of 5.7% from the November 30th total of 80,700 shares. Based on an average trading volume of 70,100 shares, the short-interest ratio is currently 1.2 days. Currently, 7.8% of the shares of the company are short sold.
Analysts Set New Price Targets
Separately, HC Wainwright upped their price target on shares of Cadrenal Therapeutics from $3.00 to $32.00 and gave the company a “buy” rating in a research note on Monday, November 11th.
Get Our Latest Analysis on Cadrenal Therapeutics
Cadrenal Therapeutics Stock Up 7.0 %
Cadrenal Therapeutics Company Profile
Cadrenal Therapeutics, Inc operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome.
See Also
- Five stocks we like better than Cadrenal Therapeutics
- Diversification Can Smooth Returns And Mitigate Portfolio Risk
- 3 Legacy Tech Companies Reemerging as AI LeadersÂ
- The Significance of Brokerage Rankings in Stock Selection
- Analysts’ Favorite Cybersecurity Stocks: 3 Top Picks
- How to Buy Cheap Stocks Step by Step
- Analysts Are Bullish: 3 Tech Giants With Upgraded Price Targets
Receive News & Ratings for Cadrenal Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cadrenal Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.